Alphatec Holdings Inc. (NASDAQ: ATEC) said its Chief Financial Officer, John Todd Koning, sold 79,789 shares of the companys common stock on March 13, 2026, according to a recent SEC filing. The sale generated approximately $986,192 in aggregate proceeds, executed at a weighted average price of $12.36 per share.
The filing shows the transactions were carried out in multiple tranches at prices ranging from $12.21 to $12.64. After completing these sales, Koning retained direct ownership of 600,721 Alphatec shares.
At the time of reporting, Alphatec stock was trading at $13.05, above the levels at which the CFO sold, although the shares are still down roughly 38% year-to-date. An InvestingPro evaluation referenced in the filing characterizes ATEC as appearing overvalued at current market prices, noting analyst price targets that range from $20 to $28. The InvestingPro platform also lists eight additional ProTips for ATEC, including items related to profitability expectations and measures of financial health.
The sales were executed under a Rule 10b5-1 trading plan that Koning adopted on December 12, 2025. The filing states the disposition was intended to cover tax obligations stemming from the vesting of restricted stock units.
Quarterly performance and analyst reactions
Alphatec reported fourth-quarter results that matched managements preannounced guidance, with earnings before interest, taxes, depreciation and amortization (EBITDA) beating consensus estimates by $2 million. The companys quarterly performance has prompted a variety of responses from equity research teams.
Piper Sandler has reiterated its Overweight rating and kept a $25.00 price target, pointing to the companys solid quarterly execution. Lake Street Capital Markets likewise maintains a Buy rating and highlights Alphatecs continued growth in the spine market as a positive.
Conversely, Stifel reduced its price target from $24 to $20, citing a weaker revenue outlook for the first quarter of 2026, though it stopped short of changing its Buy rating. Freedom Capital Markets reaffirmed its Buy stance with a $25.00 target, describing the fourth-quarter and full-year 2025 results as largely uneventful.
Governance update
In a separate corporate governance notice, Alphatec announced the retirement of director Ward W. Woods. His departure trims the board to seven members and is accompanied by a Vesting Acceleration Agreement covering his unvested restricted stock units, according to the disclosure.
Analysis and context
From a capital-markets perspective, the CFOs sale and the broad set of analyst actions together paint a picture of mixed sentiment. The sale was pre-planned under a Rule 10b5-1 program and tied to tax obligations from RSU vesting, while broker reports signal both confidence in the companys franchise in the spine market and caution about near-term revenue trends. The director retirement and the vesting acceleration agreement are governance items investors will note as they continue to evaluate board composition and equity incentive outcomes.
Key points
- Alphatec CFO John Todd Koning sold 79,789 shares on March 13, 2026, for approximately $986,192 at a weighted average price of $12.36 per share.
- Sales executed under a Rule 10b5-1 plan adopted December 12, 2025, to cover tax liabilities related to vesting restricted stock units; Koning holds 600,721 shares after the transaction.
- Alphatec reported Q4 results with EBITDA beating estimates by $2 million; analysts issued a range of responses including reiterated Buy/Overweight ratings and at least one lower price target.
Risks and uncertainties
- Near-term revenue outlook - Stifels reduction in price target reflects concern about weaker revenue in Q1 2026, which could affect market expectations and share performance.
- Valuation debate - InvestingPro analysis notes ATEC appears overvalued at current trading levels, with price targets materially above the market price, creating tension between analyst optimism and market pricing.
- Governance changes - The retirement of director Ward W. Woods and the accompanying vesting acceleration agreement may raise questions about board continuity and the impact of equity incentive adjustments.
Investors tracking Alphatec will likely weigh the procedural nature of the CFOs pre-established sale against the mixed analyst signals and the companies reported quarterly outperformance on EBITDA. The combination of tax-driven insider selling, divergent price targets, and a board-level change provides multiple threads for stakeholders to monitor as the company moves into 2026.